搜索结果：Fundamental & clinical pharmacology

Atherosclerosis, a major cause of cardiovascular diseases, has a complex pathogenesis involving lipid metabolism disorders and chronic inflammation in the vascular wall. Specialized Pro-resolving Mediators (SPMs) are endogenous lipid molecules that are synthesized from polyunsaturated fatty acids and can switch inflammation from the active phase to resolution. As a result, SPMs are of great clinical interest, as they have the potential to improve the course of atherosclerosis by reducing inflammation and promoting the stabilization of atherosclerotic plaques. However, the direct clinical application of SPMs is limited by a number of objective problems, including their chemical instability, the complexity of targeted delivery to atherosclerotic lesions, and a lack of clinical data on the long-term safety of chronic exposure to immune-modulating pathways. This review critically analyzes the key barriers to the translation of SPMs into clinical practice. The main focus is on strategies to overcome these limitations, in particular, the development of stable synthetic analogues of SPMs and innovative delivery systems. Issues of the therapeutic window, the selection of optimal points of application for therapy, and the prospects for integrating SPMs into existing treatment standards are discussed. Thus, despite the lack of clinical data on the use of SPMs for the treatment of atherosclerosis, the development of stable synthetic analogues and targeted delivery systems is a promising direction for the creation of a fundamentally new class of cardiovascular drugs.

A critical gap in current efficiency in melanoma patient treatment is the lack of a fully integrated, functional understanding of tumor evolution over time. Recent advances have fundamentally reshaped our understanding of melanoma biology, while increasing clinical complexity has highlighted the need for more comprehensive and biologically informed clinical decision-support frameworks. We propose the implementation of a multimodal disease profiling framework as a core clinical decision-support asset, enhancing treatment optimization across the full disease course in melanoma patients. By integrating proteogenomics, AI-driven digital image analysis, and structured longitudinal clinical metadata, multimodal disease profiling could provide a comprehensive and dynamically evolving view of each patient's disease. Proteogenomics reveals tumor signaling activity, protein complex dynamics, and emerging therapeutic vulnerabilities that may drive progression and resistance. In parallel, AI-enabled digital pathology analysis characterizes tumor morphology, clonal heterogeneity, and immune context, capturing spatial and functional changes associated with metastatic transition. When combined with longitudinal clinical data, these layers enable patient-specific models tracking tumor evolution, metastasis, and treatment exposure. Leveraging one of the largest melanoma biobank and database resources at the European Cancer Moonshot Center in Lund, our strategy directly addresses the recurrent transition from primary tumors to metastatic disease. This strategy positions multimodal disease profiling as a critical enabler of precision melanoma care by providing biologically grounded, evidence-based decision support, facilitating rapid and structured case assessment through multimodal insights, enabling prediction of treatment response, resistance, and disease trajectory, and supporting adaptive, evidence-informed therapeutic decision-making.

This study describes the implementation of a mechanistic subcutaneous (SC) injection model for the Open Systems Pharmacology platform. As the SC route of administration is gaining increased popularity, there is a growing need for tools to predict, analyze, and understand the SC absorption process and the mechanisms involved. The interplay between molecular, formulation, administration, and physiological properties influences both the rate and extent of drug appearance in circulation. The primary objective of this study was to provide a structural modeling basis for mechanistic simulations of drug absorption after SC administration, considering fundamental molecular properties and systemic disposition characteristics. A key aspect of the model design was the intention to support generalizability and translational application across drug characteristics and species, providing a consistent structure for both small molecules and biologics. The SC model was implemented leveraging the structure and parameterization of PK-Sim to allow unified integration to the whole-body physiologically based pharmacokinetic model. An input-response analysis and a set of case examples were conducted to visualize model responsiveness and illustrate potential application in drug development. The generic framework may also serve as the backbone for further implementations to describe complex injection and formulation dependencies. Collectively, this framework establishes a mechanistic foundation for the simulation of SC drug absorption of both small molecules and biologics, providing a basis for further development and informed evaluation across preclinical and clinical stages within the Open Systems Pharmacology platform.

Dementia, and more specifically Alzheimer's disease (AD), is a progressive neurodegenerative disorder that has become a growing health menace in the world with an escalation in incidence as well as enormous social and economic consequences. Existing pharmacological treatment including cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists are not very effective in reducing the symptoms and fail to prevent the disease process. The non-pharmacological treatment interventions such as diet, exercise and cognitive training have supportive effects and cannot be used as standalone treatments. Therapeutic gap has resulted in increased interest in complementary and alternative therapies, especially that of pleiotropic action of herbal medicines. Bacopa monnieri (BM) is an Ayurvedic herb that has historically been used to treat memory enhancement and now has both preclinical and clinical evidence supporting its ability to modulate neurotransmission, reduce oxidative stress and suppress neuroinflammation. However, such difficulties as low bioavailability, instability of the environmental factors, and variations in formulations restrict its clinical applicability. New technologies with a lot of potential such as microencapsulation technology can provide the solution to this problem by increasing stability, solubility, and targeted delivery of compounds that will increase treatment efficacy. This narrative review is a synthesis of the existing information on the pathogenesis of dementia, therapeutic approaches, and the effectiveness of BM as a complementary intervention. It points out links between traditional medicine and modern neuroscience, strengths and limitations of on-going evidence, gaps that need further research, such as long-term clinical trials, standardized formulations, and discovery of the role of BM in the gut-brain axis. BM is a prime example of how herbal medicines can be used as a complement to conventional treatment and play a role in multi-modal approaches aimed at reducing the cognitive impairment associated with dementia.

Adeno-associated viral (AAV) vectors have established themselves as a promising platform for genetic material delivery in clinical practice, evidenced by regulatory approval of multiple therapeutics. Despite proven therapeutic efficacy, safety concerns remain a critical limitation requiring systematic analysis. This review analyzes clinical data to identify mechanisms of toxicity, clinical risks, and strategies for their minimization in AAV gene therapy. The study examines dose-dependent toxicity, immune responses, and organ-specific burdens associated with systemic and local administration routes. Analysis reveals a clear correlation between systemic delivery efficacy and dose-dependent toxicity, with principal mechanisms including capsid-directed immune responses, hepatic burden, and complement system activation leading to thrombotic microangiopathy. Key determinants of the safety profile include pre-existing neutralizing antibodies, vector dose, serotype selection, and patient baseline conditions. Contemporary strategies for toxicity minimization are evolving from reactive management toward proactive risk mitigation, including prophylactic immunosuppressive regimens, vector engineering to alter tropism or reduce immunogenicity, and rigorous post-infusion monitoring. Integration of improved vector constructs, rational immunosuppressive regimens, and rigorous post-infusion surveillance has the potential to expand the therapeutic window of AAV-based gene therapy, achieving an optimal balance between efficacy and safety for a broader patient population.

Scarring remains an inevitable consequence of adult wound healing, often accompanied by functional, aesthetic, and psychological burdens. In contrast, fetal wound healing follows a fundamentally different trajectory, characterized by minimal inflammation, abundant hyaluronic acid, elevated type III collagen, and balanced matrix remodeling, culminating in regeneration without scar formation. This regenerative capacity is largely absent in adult tissues, which is the main incentive for understanding the pathophysiology of scarless healing phenotype to replicate such outcomes in adult tissues. The human amniotic membrane (hAM), as an embryogenic derivative, shares many structural and biochemical properties with fetal cutaneous tissue, positioning it as a promising biological tool to bridge adult wound healing toward a scarless, fetal-like outcome. hAM contains a rich milieu of growth factors, anti-inflammatory cytokines, and extracellular matrix components that support epithelialization, angiogenesis regulation, fibroblast modulation, and myofibroblast suppression. These effects are mediated through modulation of key signaling pathways including TGF-β/SMAD, PI3K/AKT, Wnt/β-catenin, and MAPK cascades; each central to the orchestration of fibrosis and regeneration. Furthermore, hAM's angio-modulatory behavior, antioxidant capacity, and context-dependent immune regulation contribute to a healing microenvironment that more closely mimics fetal conditions. In this review, we highlight the unique biology of fetal scarless healing which can be harnessed through the use of amniotic membrane-based therapies in adults. We highlight how the properties of hAM can help shift adult wound healing toward a more regenerative, less fibrotic outcome. We also examine different ways hAM is processed and applied in clinical settings and processing effects on anti-scar characteristic of hAM and discuss the main challenges that still need to be addressed, such as product standardization and optimizing treatment protocols, in a biomimetic way from scarless wound healing in embryo. Altogether, application of hAM presents a compelling and biologically sound approach to promote scarless wound healing in adult patients, a longstanding goal in regenerative medicine.

The teaching of pharmacology includes a fundamental understanding of ligand binding; how it is measured and how it is calculated. We sought to modernize the techniques by which ligand affinity is determined by undergraduate students and introduce them to parameter estimation through curve fitting. We taught a NanoBRET ligand binding assay to student cohorts completing their second year of undergraduate study in Natural Sciences (71 and 61 students in 2024 and 2025 respectively). The aim was to measure the affinity of fluorescent and unlabeled ligands for the β2-adrenoceptor in live cells. Affinities were then calculated from their data using a custom Microsoft Excel spreadsheet. This series of practical classes was well received by students, with most students able to follow the protocol and successfully determine ligand affinities. Furthermore, students recognized the benefit of the practical class for their education, confirming they felt it improved their understanding of how ligand affinity is calculated. We also demonstrated that this protocol could be scaled up to accommodate larger class sizes (class of 367 students studying medicine and veterinary sciences).

Central nervous system (CNS) tumors represent a heterogeneous group of neoplasms associated with significant morbidity and mortality despite their relatively low incidence. Advances in the fifth edition of the World Health Organization (WHO) classification have emphasized the integration of histopathological, immunohistochemical, and molecular features, fundamentally transforming diagnostic and prognostic frameworks in neuro-oncology. This manuscript aims to provide an overview of CNS tumor biology, focusing on key diagnostic markers, genetic and epigenetic alterations, and emerging therapeutic strategies. It further describes recent advances in multi-omics approaches and artificial intelligence, which enable deeper characterization of tumor heterogeneity and support the development of precision medicine strategies. Finally, current and emerging therapeutic modalities, including combination therapies, targeted treatments, and novel molecular targets, are examined with emphasis on overcoming resistance mechanisms and improving clinical outcomes. Overall, the integration of molecular biology, advanced diagnostics, and innovative therapeutic approaches represents a critical step toward personalized management of CNS tumors and improved patient survival.

Bacterial persister cells within extracellular polymeric substance (EPS) matrices drive antimicrobial tolerance and chronic infection relapse. Conventional bactericidal agents remain fundamentally inadequate against these dormant subpopulations due to their reliance on active cellular metabolism. This review proposes a mechanistically driven, multi-phase sequential strategy-comprising barrier disruption, metabolic resuscitation, and terminal eradication-executed via highly purified, plant-derived natural products and advanced delivery systems. We synthesize recent pharmacological evidence regarding the anti-biofilm mechanisms of these active monomers and their integration with microenvironment-responsive strategies. A three-phase framework is delineated. Phase I utilizes epigallocatechin gallate (EGCG) and baicalin to physically degrade the EPS architecture and antagonize quorum sensing networks. Phase II employs Astragalus polysaccharides (APS) and exogenous metabolites to restore microbicidal host immunity and reactivate bacterial central carbon metabolism. Phase III leverages this reactivated state, utilizing berberine and shikonin to induce lethal reactive oxygen species (ROS) accumulation and terminal respiratory arrest. To resolve the pharmacokinetic limitations of these phytochemicals, we conceptualize integrating stimuli-responsive delivery systems for chronologically programmed drug release triggered by biofilm microenvironmental gradients. Ultimately, this sequential "disrupt-awaken-kill" strategy offers a potent framework to eradicate recalcitrant persisters, though translating these multi-component therapies into clinical practice requires overcoming existing manufacturing and regulatory complexities.

Increased access to OTC has enabled the collection, with patient consent, of research tissue samples from healthy premenopausal patients. These samples are a critical resource to advance our understanding of fundamental ovarian biology. When choosing a preservation method for the tissue collected for research purposes, it is important to define what outcomes are desired from tissue analysis. If tissue is preserved in certain ways the types of analyses available will be limited. This review details various processing methods that can be undertaken in the operating room, or after transportation, and examples of experimental approaches that are applicable to ovarian tissue research.

Few conditions in reproductive medicine rival polycystic ovary syndrome (PCOS) in terms of clinical breadth and global impact. Affecting roughly 6-21% of women of childbearing age depending on which diagnostic criteria are applied PCOS sits at the intersection of endocrinology, metabolism, and gynecology, making it difficult to capture within any single disciplinary lens. Its hallmarks are well rehearsed: excess androgens, disrupted ovulation, and the characteristic follicular architecture seen on pelvic ultrasound. Yet what makes PCOS genuinely challenging is the degree to which these reproductive features overlap with far-reaching metabolic consequences, including insulin resistance, type 2 diabetes, lipid abnormalities, and a meaningfully elevated cardiovascular risk profile that persists well beyond the fertile years. Despite several decades of sustained investigation, the origins of PCOS remain imperfectly understood. Genetic susceptibility, epigenetic programming, environmental chemical exposures, and modern dietary habits all appear to play contributory roles, though no single culprit has emerged. The molecular picture is equally layered: aberrant insulin signaling feeds androgen overproduction, gonadotropin secretion goes out of balance, inflammatory cytokines accumulate, oxidative injury mounts, and more recently the gut microbial community has been implicated as an additional participant in this cascade. Diagnosis is further complicated by the phenotypic variability of the syndrome, with different criteria yielding meaningfully different patient populations. Treatment, in turn, requires individualization; lifestyle change, hormonal therapies, insulin sensitizers, and an expanding repertoire of repurposed drugs and plant-based agents each address different facets of a fundamentally heterogeneous disorder. This review provides a comprehensive and integrated account of PCOS across its full biological and clinical spectrum. It covers epidemiology, clinical presentation, risk factors, and current diagnostic frameworks. Pathophysiological mechanisms are examined in depth. A central and distinctive focus of this review is the experimental preclinical landscape. Established animal induction models, letrozole, dehydroepiandrosterone (DHEA), testosterone/dihydrotestosterone propionate, and high-fat diet protocols are critically evaluated for their translational relevance. Drawing on these models, we comprehensively catalogue protective agents across four systematic tables, encompassing both repurposed pharmaceuticals (metformin, GLP-1 receptor agonists, SGLT-2 inhibitors, statins, melatonin) and bioactive natural compounds (curcumin, berberine, quercetin, fisetin, myricetin, apigenin, and others), detailing their induction models, mechanistic pathways, and therapeutic outcomes. Together, this review aims to serve as a single, authoritative reference bridging basic science, translational pharmacology, and clinical practice in PCOS, while identifying the most promising avenues for future research and personalized therapeutic development.

Atherosclerosis (ATS) remains a leading cause of global morbidity and mortality, driven by complex interactions among chronic inflammation, oxidative stress, and lipid accumulation within arterial walls. Although conventional therapies, including lipid-lowering and anti-inflammatory agents, have demonstrated clinical efficacy, their therapeutic potential is often limited by systemic side effects, suboptimal bioavailability, and poor site specificity. In this context, nanodelivery systems have emerged as a transformative approach to enhance therapeutic precision by enabling targeted, controlled, and stimuli-responsive delivery of drugs and genetic materials directly to atherosclerotic plaques. Recent advances in nanomedicine have led to the development of multifunctional nanoparticles capable of responding to key pathological features of ATS, such as elevated reactive oxygen species levels, acidic microenvironments, and dysregulated enzymatic activity, thereby improving therapeutic efficacy while minimizing off-target effects. Furthermore, nanoparticle-based platforms have shown significant promise for delivering nucleic acids, including small interfering RNAs and microRNAs, thereby facilitating modulation of critical molecular pathways involved in plaque progression and stabilization. This review provides a comprehensive overview of recent progress in nanoparticle-mediated drug and gene delivery systems for ATS, with particular emphasis on targeting strategies, microenvironment-responsive nanocarriers, and emerging therapeutic platforms for ATS. In addition, current challenges related to toxicity, large-scale manufacturing, reproducibility, and clinical translation are critically discussed, highlighting the need for standardized protocols and rigorous safety evaluations to advance the clinical applicability of nanomedicine in ATS management.

Osteoporosis (OP) is a gradual metabolic bone disease characterized by decreased bone mass and degradation of bone microarchitecture. It affects hundreds of millions of people globally and places considerable pressure on healthcare systems. Current pharmacological treatments, such as bisphosphonates, selective estrogen receptor modulators, and anabolic agents, can reduce fracture risk; however, their prolonged use is limited by significant adverse effects, elevated treatment costs, and a lack of sustained disease remission. Their constraints have intensified interest in restorative approaches utilizing mesenchymal stem cells (MSCs). In the past 20 years, MSCs have emerged as attractive treatment options for OP due to their capacity to differentiate into osteoblasts, modulate immune responses, and exert paracrine effects. Bone marrow-MSCs are the best characterized; nevertheless, MSCs obtained from adipose tissue, umbilical cord, and dental pulp have distinct benefits. Preclinical data demonstrate that direct MSC transplantation enhances bone mineral density, promotes osteoblast production, and reestablishes the equilibrium of bone remodeling in many OP models, including Ovariectomy, glucocorticoid-induced OP, and diabetic OP. Nonetheless, significant obstacles persist: insufficient targeting of osteoporotic bone surfaces, suboptimal cell viability and integration, donor heterogeneity, and unresolved safety concerns. The discovery that the secretome and exosomes (EXOs) produced from MSCs recapitulate several therapeutic advantages of the original cells has initiated a transition toward cell-free methodologies. EXOs produced from MSCs include osteogenic microRNAs (including miR-150-3p and miR-21), inhibit NLRP3 inflammasome activation in osteoclasts, promote macrophage polarization toward an M2 phenotype via TRIM25/TREM1 signaling, and facilitate angiogenesis through the activation of the PI3K/Akt pathway. Furthermore, nanoparticle engineering and combinatorial medicines are advancing to enhance targeting and therapeutic efficacy.

Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most prevalent neurodegenerative disorders, while the therapeutic efficacy of current drugs for both diseases remains limited, with unfavourable side effects. The fruit of Areca catechu L. (AC) is recognised as a popular chewing item across China and Southeast Asia and has been used for centuries as a traditional remedy, ranging from relieving digestive issues to depression. The neuroprotective role of AC has been underscored in previous studies; however, its mechanisms of action remain unclear. The present study aimed to investigate anti-neurodegenerative mechanisms of AC for the treatment of AD and PD. An integrated approach combining untargeted metabolite profiling, network pharmacology, bioinformatics analysis, and molecular docking was utilised. Experimental validation was performed using in vitro cell-based and in vivo models. The study revealed TNF-α, IL-1β, IL-6, CASP3, MAPK3, and AKT1 as top-ranked hub targets by which AC exerts its action on AD and PD. Enrichment analyses of these genes identified significant biological and functional pathways involved in neuroinflammation, apoptosis, and AD. Experimental validation showed that AC extracts significantly downregulated hub gene expressions in the neuroinflammatory BV-2 microglia cell model and prolonged the survival of the transgenic Caenorhabditis elegans AD model. Docking analysis suggested lucidine B, oxolucidine B, solanocapsine, evodiamine, and liquiritigenin are the principal phytocompounds underlying the neuroprotective properties of AC. The findings revealed the pharmacological mechanisms of AC and highlighted its potential value as an effective, multitargeting natural agent to address challenges in AD and PD therapies.

Pain is a major clinical challenge characterized by maladaptive changes in somatosensory processing, leading to persistent hypersensitivity and limited therapeutic options. Voltage-gated A-type potassium channels have emerged as key determinants of neuronal excitability in both peripheral and central nociceptive pathways. By activating at subthreshold membrane potentials and rapidly inactivating, A-type potassium channels critically regulate action potential initiation, dendritic signal integration, and synaptic transmission, thereby acting as an intrinsic "brake" on pain signaling. A growing body of evidence demonstrates that downregulation or functional impairment of A-type potassium channel is a common mechanism underlying neuronal hyperexcitability in pain states, including neuropathic, inflammatory, and chemotherapy-induced pain. In dorsal root ganglion neurons and spinal dorsal horn circuits, reduced A-type potassium current contributes directly to mechanical allodynia, hyperalgesia, and central sensitization. These pathological changes are driven by complex regulatory processes, including inflammatory signaling cascades, transcriptional and post-transcriptional modulation, and post-translational modifications that dynamically suppress channel function. Importantly, A-type potassium channels activity is not fixed but highly context-dependent, varying across cell types, subcellular compartments, and disease conditions. Emerging evidence indicates that auxiliary subunits and associated regulatory networks play critical roles in shaping A-type potassium channels function and determining their contribution to pain processing. This complexity suggests that targeting A-type potassium channel complexes and their regulatory pathways may provide more precise and effective analgesic strategies compared with conventional approaches.This review summarizes current advances in the role of A-type potassium channels in pain mechanisms, with a focus on their contributions to neuronal hyperexcitability, regulatory networks, and disease-specific alterations. We further discuss the therapeutic potential of A-type potassium channels and highlight future directions for developing selective modulators aimed at restoring excitability balance in pain disorder.

Sudan virus (SUDV; species Orthoebolavirus sudanense) remains a major public health threat, yet research is limited by restricted access to biosafety level 4 (BSL-4) facilities. To address this, we developed a biologically contained SUDV lacking the essential VP30 gene, restricting replication to VP30-expressing cells. We demonstrate efficient virus rescue, strict functional and genetic containment, and replication kinetics comparable to wild-type SUDV in permissive cells. Using heterologous VP30-expressing cell lines, we observe strong cross-functionality among orthoebolaviruses, whereas Marburg virus VP30 shows minimal activity, highlighting genus-specific constraints. The system supports high-throughput antiviral screening and confirms robust activity of remdesivir. In addition, resistance profiling identified substitutions at residue F549 of viral polymerase L as key determinants for remdesivir resistance, with additional mutations at M675. Together, this biologically contained SUDV system enables safe study of viral replication, antiviral discovery, and resistance evolution under lower biosafety conditions.

The kynurenine pathway (KP), serving as the principal catabolic route for tryptophan metabolism, has emerged as a potential regulatory mechanism in neurological and psychiatric pathophysiology. This biochemical cascade produces functional metabolites - particularly kynurenine (KYN), kynurenic acid (KYNA), and quinolinic acid (QUIN) - that exert bidirectional neuromodulatory effects through glutamatergic transmission and nicotinic receptor signaling. Current research reveals three key challenges: (1) incomplete elucidation of spatiotemporal-specific metabolite dynamics across CNS compartments, (2) paradoxical neuroprotective/neurotoxic effects contingent on concentration gradients, and (3) limited clinical translatability of preclinical findings. While enzyme-targeted interventions (including IDO, TDO, KMO, and KAT) show promise in experimental models, their clinical translation faces challenges including poor blood-brain barrier penetrance, off-target effects that perturb the KYNA/QUIN ratio, and interspecies differences in KP enzyme expression profiles. This narrative review systematically evaluates contemporary preclinical and clinical evidence to delineate the pathway's complex neurobiological roles. Our analysis underscores the necessity for novel therapeutic approaches capable of region-selective KP modulation while preserving the critical equilibrium between neuroprotective and neurotoxic metabolites, a fundamental requirement for advancing treatment paradigms in refractory neuropsychiatric disorders.

Aim: To study the potential mechanisms underlying the beneficial nephroprotective effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors. Materials and Methods: An analysis of literature sources was conducted regarding the clinical, epidemiological, and fundamental aspects of the nephroprotective effects of SGLT-2 inhibitors. For this purpose, articles were searched for and selected in the PubMed database using the following keywords: "sodium-glucose cotransporter-2 inhibitors," "heart failure," "chronic kidney disease," and "cardiorenal syndrome," with a primary focus on studies published in the last 5 years. To provide context and explain the underlying mechanisms, several classical and fundamental studies relevant to the aim of the review were also included. Conclusions: SGLT-2 inhibitors exert nephroprotective effects through a complex of interrelated hemodynamic, metabolic, and cellular-molecular mechanisms that are largely independent of their hypoglycemic action. The combination of these mechanisms explains the clinically proven nephroprotective effect of SGLT-2 inhibitors in both patients with and without DM and justifies considering them not only as glucose-lowering agents but also as fundamental agents of pathogenetic therapy for chronic kidney disease.

Doxorubicin (DOX) remains a foundation of cancer treatment; however, its clinical utility is seriously restricted by measurements of subordinate and frequently irreversible cardiotoxicity. In spite of the fact that dexrazoxane is as of now the as it were affirmed cardioprotective specialist, its limited viability and clinical restrictions highlight the require for elective methodologies. Developing prove shows that DOX-induced cardiotoxicity could be a systems-level clutter driven essentially by mitochondrial brokenness, metabolic resoluteness, disabled quality control, and controlled cell passing pathways. This audit fundamentally looks at rising cardioprotective methodologies past dexrazoxane, with a center on sodium glucose cotransporter 2 (SGLT2) inhibitors, medicate repurposing approaches, and mitochondrial-targeted treatments. We synthesize unthinking bits of knowledge and translational prove to compare these techniques in terms of robotic breadth and clinical status. SGLT2 inhibitors rise as the most clinically developed and robotically integrator choice, though repurposed drugs and mitochondrial-directed mediations offer complementary but variable potential. Finally, we highlight future bearings emphasizing combination treatments and accuracy cardioprotection to realize solid cardiac conservation in anthracycline-treated patients.